Source
Medrxiv
This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.
Background Underrepresentation of minority groups in clinical trials worsens health disparities and reduces generalizability of results. Transthyretin-associated cardiac amyloidosis (ATTR), is a condition that disproportionately impacts some racial and ethnic groups yet the extent to which trial enrollment reflects disease burden remains unclear. Misalignment between disease prevalence and trial representation may delay treatment development and increase the economic burden of late diagnosis and mismanagement.
News Url